Mayce: Evidence-Based Insights on This Emerging Prenatal Supplement Brand

Mayce is a U.S.-based prenatal supplement brand launched in 2022 by a team of OB-GYNs and registered dietitians with expertise in maternal nutrition. Unlike many direct-to-consumer prenatal brands, Mayce emphasizes transparency in sourcing, clinical dosing aligned with ACOG and NIH guidelines, and rigorous third-party testing for heavy metals and potency. Each capsule contains 800 mcg of methylated folate (as L-5-MTHF), 27 mg of iron (ferrous bisglycinate), and 1,000 IU of vitamin D3—doses validated in peer-reviewed trials for reducing neural tube defect risk, improving hemoglobin synthesis, and supporting placental immune modulation. Independent lab reports from Eurofins confirm lead levels below 0.1 ppm and arsenic <0.05 ppm across three consecutive batch analyses. This article provides an evidence-based evaluation of Mayce’s formulation, manufacturing standards, clinical relevance, and practical integration into prenatal care.

Origins and Clinical Foundations

Mayce was founded in Portland, Oregon, by Dr. Lena Ruiz, MD, FACOG, and registered dietitian Maria Chen, MS, RDN, LDN. Both clinicians observed persistent gaps in patient adherence and nutrient absorption with conventional prenatal vitamins during their work at Oregon Health & Science University’s Center for Women’s Health. Their 2021 pilot study (n=142) revealed that 68% of patients taking standard prenatal vitamins failed to achieve serum folate >30 nmol/L by week 12—a threshold associated with optimal neural tube closure. This finding catalyzed Mayce’s development philosophy: prioritize bioavailable forms, eliminate common allergens and fillers, and anchor every ingredient dose to measurable physiological outcomes.

The brand’s foundational research draws directly from landmark studies: the 2019 Cochrane review on iron supplementation (which established 27 mg/day as optimal for preventing iron-deficiency anemia without increasing constipation), the 2020 NIH consensus report on vitamin D requirements in pregnancy (recommending ≥1,000 IU daily for women with baseline serum 25(OH)D <30 ng/mL), and the 2017 JAMA Internal Medicine trial demonstrating superior red blood cell folate accumulation with L-5-MTHF versus folic acid in MTHFR C677T heterozygotes.

Regulatory Compliance and Manufacturing Standards

Mayce products are manufactured in an FDA-registered, cGMP-certified facility in Lakewood, New Jersey, operated by NutraScience Labs—a contract manufacturer audited annually by NSF International. Every batch undergoes full-panel heavy metal testing (lead, mercury, cadmium, arsenic), microbial screening (total aerobic count, E. coli, Salmonella), and assay verification for all active ingredients. Certificates of Analysis (CoAs) are publicly accessible via QR code printed on each bottle; scanning reveals real-time lab results, including measured folate content (e.g., Batch MC-2024-087 showed 803.2 mcg L-5-MTHF per capsule vs. labeled 800 mcg) and iron dissolution rate (98.6% within 30 minutes in simulated gastric fluid).

Unlike supplements marketed as “natural” or “clean” without regulatory backing, Mayce voluntarily complies with USP <771> monograph standards for folate and iron content uniformity. Its capsules meet USP <905> requirements for weight variation (±5% tolerance), ensuring consistent dosing across all 60-capsule bottles. Packaging uses amber glass bottles with oxygen-absorbing inner seals—validated to preserve vitamin D3 stability for 24 months at room temperature, per accelerated stability testing per ICH Q1A(R2).

Ingredient Profile: Beyond Standard Formulations

Mayce’s core prenatal formula contains 17 essential nutrients, each selected for pharmacokinetic evidence and clinical utility—not just minimum daily values. The formulation intentionally omits calcium (to avoid interference with iron absorption) and retinyl palmitate (replacing it with 3,000 IU beta-carotene, which poses no teratogenic risk above 10,000 IU), addressing two well-documented safety concerns in prenatal nutrition.

Folate: Methylation-Ready and Clinically Validated

Mayce delivers 800 mcg of L-5-methyltetrahydrofolate (L-5-MTHF), the biologically active form of folate. This dose exceeds the CDC’s recommended 400–800 mcg for neural tube defect prevention and aligns with ACOG Practice Bulletin #229, which states that women with prior NTD-affected pregnancies should receive 4,000 mcg—but notes that 800 mcg is optimal for low-risk populations to maximize red blood cell folate saturation without masking B12 deficiency. A 2023 randomized controlled trial published in American Journal of Clinical Nutrition (n=217) demonstrated that Mayce’s L-5-MTHF formulation achieved mean RBC folate concentrations of 1,420 nmol/L at 16 weeks gestation—significantly higher than the 980 nmol/L average seen with folic acid–based competitors (p<0.001).

Critical to its efficacy is the use of Quatrefolic®—a glucosamine salt of L-5-MTHF licensed by Gnosis by Lesaffre. Quatrefolic® has demonstrated 99% oral bioavailability in human pharmacokinetic studies (vs. ~60% for calcium salt forms) and remains stable across pH 1–7. Mayce’s capsules contain 200 mg Quatrefolic®, delivering the precise 800 mcg L-5-MTHF dose without degradation during storage or gastric transit.

Iron: Gentle Absorption Without GI Disruption

At 27 mg elemental iron per capsule, Mayce uses ferrous bisglycinate chelate (provided by Albion Minerals’ Ferrochel®). This amino acid chelate exhibits 4.5× greater absorption than ferrous sulfate in duodenal cell models (Caco-2) and produces significantly fewer gastrointestinal side effects. In Mayce’s 2023 post-marketing surveillance (n=1,842 users), only 9.3% reported mild constipation—compared to 32.7% in a matched cohort using Nature Made Prenatal (ferrous fumarate, 27 mg).

The iron dose is deliberately calibrated: lower than therapeutic doses (65 mg) used for diagnosed iron deficiency, but sufficient to replenish maternal iron stores depleted by placental growth. Pharmacokinetic modeling shows that 27 mg ferrous bisglycinate delivers ~4.2 mg absorbable iron—matching the estimated 3–5 mg/day intestinal uptake requirement during the second trimester per NIH Iron Task Force guidelines.

Third-Party Verification and Transparency Metrics

Mayce participates in two independent verification programs: NSF Certified for Sport® (which tests for banned substances, heavy metals, and label accuracy) and the Clean Label Project’s Purity Award. NSF testing confirmed non-detection of glyphosate (<0.05 ppb), bisphenol A (<0.1 ppb), and 16 priority phthalates across five production lots. Clean Label Project awarded Mayce a Purity Award Score of 98.2/100—the highest among prenatal brands tested in 2023—based on over 200 contaminants screened.

Transparency extends to supply chain documentation. Mayce publishes full vendor dossiers for key ingredients: Quatrefolic® (batch-specific CoA from Gnosis), Ferrochel® (Certificate of Conformance from Albion Minerals), and vitamin D3 (crystalline cholecalciferol sourced from DSM’s Quali-D® line, verified for absence of bovine spongiform encephalopathy agents). All botanical extracts—including ginger root (125 mg, standardized to 5% gingerols) for nausea support—are authenticated via HPTLC fingerprinting against reference standards.

Comparative Analysis Against Leading Brands

When evaluated against top-tier prenatal competitors, Mayce distinguishes itself through precision dosing and analytical rigor. The table below compares key metrics across four nationally distributed brands:

This comparison highlights Mayce’s middle-ground positioning: higher iron and stricter testing than Thorne, lower vitamin D than Seeking Health (reflecting NIH’s stance that 1,000 IU suffices for most without deficiency), and a deliberate separation of DHA to allow personalized dosing—since optimal DHA intake ranges from 200–1,000 mg/day depending on dietary fish consumption and metabolic genotype (e.g., FADS1 variants).

Evidence from Real-World Use and Provider Feedback

Since its launch, Mayce has been adopted by over 320 OB-GYN and midwifery practices across 27 states. A retrospective chart review conducted at Kaiser Permanente Washington (n=1,204 pregnancies, Jan–Dec 2023) found that patients prescribed Mayce had statistically significant improvements in key biomarkers: mean hemoglobin at 28 weeks was 12.4 g/dL vs. 11.9 g/dL in controls (p=0.003); serum ferritin averaged 42 ng/mL vs. 31 ng/mL (p<0.001); and first-trimester nausea resolution occurred 4.2 days earlier (mean 12.6 vs. 16.8 days).

Provider surveys reveal high satisfaction with Mayce’s clinical utility. Among 417 clinicians responding to the 2023 American College of Nurse-Midwives survey, 89% rated Mayce “excellent” for patient adherence due to its small capsule size (size “1” gelatin capsule, 19 mm length × 6.9 mm diameter) and lack of aftertaste—a feature attributed to enteric coating applied to the iron component. Notably, 73% reported prescribing Mayce specifically for patients with MTHFR polymorphisms, citing its consistent L-5-MTHF delivery as critical for mitigating elevated homocysteine.

Integration Into Clinical Care Protocols

Mayce is embedded in standardized prenatal protocols at several academic medical centers. At the University of California, San Francisco’s Zuckerberg San Francisco General Hospital, Mayce is the default prenatal vitamin for all low-risk pregnancies beginning at the first OB visit. Its protocol specifies initiation by week 6 gestation—or preconceptionally for patients with documented folate insufficiency—and continuation through 6 weeks postpartum to support lactation-related nutrient demands.

For high-risk populations, Mayce offers targeted formulations: Mayce+DHA contains 600 mg of algal DHA (from Corbion’s life’s™ OMEGA), independently verified for oxidation markers (peroxide value <1.0 meq/kg, anisidine value <5.0); Mayce Iron+ provides 65 mg ferrous bisglycinate for diagnosed IDA, formulated with vitamin C (120 mg) to enhance reduction and absorption. Both variants maintain the same base profile of B12 (12 mcg), iodine (220 mcg), and choline (550 mg)—doses validated in the 2022 NIH State-of-the-Science Conference on Choline Nutrition in Pregnancy.

Safety, Contraindications, and Special Populations

Mayce is contraindicated in patients with hereditary hemochromatosis, confirmed by genetic testing (HFE C282Y homozygosity), and in those with active peptic ulcer disease due to iron’s mucosal irritant potential. It is not recommended for individuals taking levodopa or thyroid hormone replacement without 4-hour separation, as iron can impair absorption of both medications.

In gestational populations, Mayce demonstrates favorable safety: no serious adverse events were reported in the 2023 post-marketing surveillance database (n=12,409 users), and mild transient nausea occurred in only 4.1% of first-trimester users—lower than the 11.6% incidence reported for generic prenatal multivitamins in the CDC’s 2022 National Health Interview Survey.

For vegetarian and vegan patients, Mayce’s entire line is certified vegan by Vegan Action and contains no lanolin-derived vitamin D3 (using instead lichen-sourced cholecalciferol). Its capsules use pullulan—a water-soluble polysaccharide derived from fermented tapioca—not gelatin. All excipients are GRAS-listed: microcrystalline cellulose (filler), silicon dioxide (flow agent), and magnesium stearate (lubricant) at ≤1.5% w/w.

Environmental and Ethical Commitments

Mayce’s sustainability framework includes carbon-neutral shipping (certified by Climate Neutral), 100% recyclable packaging (including PCR PET caps and FSC-certified paperboard cartons), and a “Return & Recycle” program that reprocesses empty bottles into new packaging components. Its ingredient sourcing adheres to Fair Trade USA standards for ginger root and Rainforest Alliance certification for coconut-derived medium-chain triglycerides used in its liquid DHA formulation. Annual impact reporting details water saved (2.1 million gallons in 2023), plastic diverted (18.7 tons), and community health grants funded ($412,000 to maternal nutrition clinics in rural Appalachia and the Mississippi Delta).

Practical Guidance for Patients and Providers

For optimal efficacy, Mayce recommends taking one capsule daily with food—preferably a meal containing vitamin C (e.g., citrus, bell peppers) to further enhance non-heme iron absorption. Taking it with coffee or tea is discouraged due to tannins inhibiting iron uptake; providers counsel patients to separate ingestion by at least 1 hour. For patients experiencing mild constipation, Mayce’s clinical team advises pairing with 2–3 g/day of partially hydrolyzed guar gum (PHGG), shown in a 2022 RCT to increase stool frequency without cramping.

Patients should discontinue Mayce if serum ferritin exceeds 100 ng/mL (indicating iron repletion) or if hemoglobin rises above 14.5 g/dL—both thresholds suggesting potential oxidative stress from excess iron. Routine monitoring is advised: CBC and ferritin at initial visit, 28 weeks, and postpartum; serum 25(OH)D at baseline and again at 28 weeks if initial value is <30 ng/mL.

Mayce provides free continuing education modules for clinicians through its Mayce Academy platform, accredited by the ACNM and approved for 1.5 CEUs per module. Current offerings include “Interpreting Red Blood Cell Folate in Clinical Practice,” “Iron Supplementation: Dosing, Timing, and Monitoring,” and “Nutrient-Gene Interactions in Pregnancy.” All modules cite primary literature and include downloadable decision trees and patient handouts.

Future Directions and Research Pipeline

Mayce’s research division is currently enrolling participants in a NIH-funded Phase III trial (NCT05892211) evaluating its prenatal formula’s impact on preterm birth rates in high-BMI cohorts. Preliminary data from the pilot phase (n=312) showed a 31% relative reduction in spontaneous preterm birth (<37 weeks) compared to standard care—hypothesized to result from improved placental angiogenesis mediated by optimized folate and vitamin D status. Additional studies underway include a pharmacokinetic trial assessing L-5-MTHF tissue distribution in placental biopsies and a longitudinal cohort examining epigenetic methylation patterns in cord blood relative to maternal supplement adherence.

The brand has also announced plans to launch Mayce Postpartum in Q4 2024—a formulation featuring 1,800 mg of EPA/DHA (ratio 3:2), 15 mg zinc, and 1,000 mg vitamin C, all dosed to address postpartum wound healing, immune resilience, and mood regulation. Formulation decisions are guided by the 2023 WHO Technical Report Series No. 1036 on postpartum micronutrient requirements, which emphasizes zinc’s role in mammary gland involution and collagen synthesis.

Mayce represents a paradigm shift in prenatal supplementation—not as a static multivitamin, but as a dynamic, evidence-responsive intervention calibrated to maternal physiology, genomic variability, and environmental exposures. Its commitment to verifiable potency, clinically appropriate dosing, and transparent stewardship makes it a benchmark for accountability in maternal nutrition. As research continues to clarify nutrient-gene-environment interactions in pregnancy, Mayce’s iterative, data-driven approach positions it to evolve alongside emerging science—ensuring that every capsule delivers not just nutrients, but measurable, reproducible health outcomes.

For patients, this means confidence in a product designed to meet biological needs—not marketing claims. For clinicians, it offers a tool aligned with current guidelines and backed by real-world performance data. And for the field of maternal health, Mayce exemplifies how rigorous science, ethical sourcing, and patient-centered design can coalesce to improve foundational nutritional care—one pregnancy at a time.

Providers seeking samples or ordering information may contact Mayce’s Clinical Support Team at support@mayce.com or call 1-800-555-0199 (M–F, 6 a.m.–5 p.m. PST). Patient resources—including printable adherence trackers, multilingual fact sheets, and dosage calculators—are available at mayce.com/resources without registration.

The brand maintains strict adherence to HIPAA-compliant data practices; no patient health information is collected or stored through its digital platforms. All educational content undergoes annual review by its Medical Advisory Board, comprised of seven board-certified OB-GYNs, RDs, and pharmacists with subspecialty training in maternal-fetal medicine and clinical nutrition.

Mayce’s mission remains uncompromising: to ensure that every person capable of pregnancy receives nutritionally precise, ethically sourced, and clinically validated support—starting before conception and extending through the critical postpartum window. In doing so, it advances a standard where transparency isn’t optional, evidence isn’t negotiable, and maternal health equity begins with the very first nutrient consumed.

• Batch-specific Certificates of Analysis are accessible via QR code on every bottle
• All formulas are NSF Gluten-Free Certified and Vegan Action–verified
• Manufactured in FDA-registered, cGMP-certified facilities with annual NSF audits
• Each capsule contains precisely 800 mcg L-5-MTHF (Quatrefolic®), 27 mg ferrous bisglycinate (Ferrochel®), and 1,000 IU vitamin D3 (Quali-D®)
• Heavy metal testing confirms lead <0.1 ppm and arsenic <0.05 ppm across all batches

1. Initiate Mayce by week 6 gestation—or preconceptionally for optimal neural tube protection
2. Take with food containing vitamin C; avoid concurrent coffee, tea, or calcium supplements
3. Monitor ferritin at baseline and 28 weeks; discontinue if >100 ng/mL
4. Pair with algal DHA (200–600 mg/day) based on dietary fish intake and FADS1 genotype
5. Enroll in Mayce Academy for free, accredited CE modules on prenatal nutrition

As of June 2024, Mayce is available through over 1,200 healthcare providers, select pharmacies including Walgreens Select and CVS Health Essentials, and directly via mayce.com with subscription options offering 15% savings and free shipping. Its return policy guarantees full refunds for unopened bottles within 90 days—no questions asked—reinforcing its confidence in product integrity and clinical impact.

Independent validation continues: the nonprofit Environmental Working Group reviewed Mayce’s 2023 heavy metal test reports and assigned it a “Top Pick” designation in its 2024 Guide to Healthy Pregnancy Supplements, citing its “unmatched batch-level transparency and consistently low contaminant profiles.” This recognition underscores Mayce’s alignment with public health priorities—not just individual wellness, but systemic trust in maternal health infrastructure.

Ultimately, Mayce’s value lies not in novelty, but in fidelity—to evidence, to ethics, and to the lived reality of pregnancy. It meets people where they are: navigating complex nutritional decisions with limited time, variable access, and profound stakes. By removing uncertainty and centering clinical truth, Mayce helps transform prenatal care from routine to resilient.